Please assess the completion status of the following clinical trial:

Trial Title: Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed solid tumors or lymphomas.~* Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy.~* One or more tumors measurable on radiograph or CT scan, or evaluable disease (e.g., malignant ascites).~* Karnofsky performance status of greater than or equal to 70.~* Life expectancy of at least 3 months.~* Age at least 18 years.~* Patients must have central IV access, or agree to the insertion of a central IV line.~* Normal oxygen saturation by pulse oximetry on room air~* A negative pregnancy test (if female).~* Acceptable liver function as evaluated by laboratory results~* Acceptable renal function as evaluated by laboratory results~* Acceptable hematologic status as evaluated by laboratory results~* No clinically significant urinalysis abnormalities~* Acceptable coagulation status as evaluated by laboratory results~* Fertile men and women must use effective contraceptive methods during the study.~Exclusion Criteria:~* Seizure disorders requiring anticonvulsant therapy.~* Known brain metastases (unless previously treated and well controlled for a period of greater than or equal to 3 months).~* Severe chronic obstructive pulmonary disease with hypoxemia, or an uncorrectable pulmonary compromise.~* Major surgery, other than diagnostic surgery, within 4 weeks prior to the first dose of test drug.~* Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.~* Pregnant or nursing women.~* Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within one month prior to study entry (6 weeks for nitrosoureas or Mitomycin C).~* Unwillingness or inability to comply with procedures required in this protocol.~* Known infection with HIV, hepatitis B, or hepatitis C.~* Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis.~* Patients who are currently receiving any other investigational agent.~* Patients who have exhibited allergic reactions to a similar structural compound (e.g., fluoroquinolones, biological agent or formulation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Quarfloxin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).